Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Novartis AG (NVS) Price & Performance

GraniteShares 2x Long NVDA Daily ETFTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

GraniteShares 2x Long NVDA Daily ETF vs Novartis AG — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $31.43, while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and Novartis AG is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.

	NVDL	NVS
Sector	Leveraged / Inverse	Health
52-Week High	$43.02	$168.62
52-Week Low	$21.76	$113.50
Market Cap	—	$290.25B
Enterprise Value	—	$330.27B
Dividend Yield	—	3.17%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVDL

View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About GraniteShares 2x Long NVDA Daily ETF

NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.